Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHIR-98023
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral (preclinical)
01
Overview
CHIR-98023 is a potent, selective, and reversible small molecule inhibitor of glycogen synthase kinase 3 (GSK3), targeting both GSK3α and GSK3β isoforms with IC50 values of 10 nM and 6.7 nM respectively[1][3]. It has been studied primarily in preclinical models for its effects on glucose metabolism and insulin sensitivity. In animal studies, oral administration of CHIR-98023 improved insulin sensitivity and increased liver glycogen synthesis in insulin-resistant rats[5]. The compound is used as a research tool to investigate the role of GSK3 in metabolic diseases such as diabetes.
- Other names
- UNII-CMQ1L0E91YUNII-CMQ-1L0E91YUNII-CMQ 1L0E91Y
02
Targets
GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on CHIR-98023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHIR-98023.